Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2017-02-08 Capital/Financing Update
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2017
Capital/Financing Update Classification · 95% confidence The document is a letter from an underwriter (National Securities Corporation) to the SEC regarding a Registration Statement on Form S-1 for Moleculin Biotech, Inc. It specifically mentions concurrence in the acceleration request for the effective date of the registration statement. This is related to a capital raising process and the registration of securities. The document is short (1040 characters) and is a correspondence related to a financing activity, not a full report or financial statement. Therefore, it fits best under Capital/Financing Update (CAP).
2017-02-08 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. It is a correspondence related to a securities registration process, not a financial report or announcement of results. The document is short (880 characters) and is a formal request rather than a report or announcement. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory communications that do not fit other categories.
2017-02-08 English
Capital/Financing Update 2017
Capital/Financing Update Classification · 95% confidence The document is a letter from Roth Capital Partners, the underwriter, to the SEC regarding a Registration Statement on Form S-1 for Moleculin Biotech, Inc. It specifically addresses concurrence in the acceleration request for the effective date of the registration statement. This is related to a capital raising process and the filing of a registration statement for securities offering. The document is short (1035 characters) and is a correspondence related to the registration process, not the registration statement itself or a financial report. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2017-02-08 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A Registration Statement Amendment No. 2 filed with the SEC under the Securities Act of 1933. It is a registration statement for a securities offering by Moleculin Biotech, Inc., detailing the proposed sale of units consisting of common stock and warrants. The document includes offering details, underwriting information, risk factors, and other disclosures typical of a registration statement for an initial or follow-on public offering. This type of filing is related to capital raising activities and financing updates rather than financial reports, management changes, or other categories. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication notice but the actual registration statement amendment filing.
2017-02-07 English
FWP
Capital/Financing Update Classification · 95% confidence The document is a Free Writing Prospectus (FWP) related to a public offering filed pursuant to Rule 433 of the Securities Act of 1933. It includes detailed information about the company's drug pipeline, clinical trial data, intellectual property status, and market overview. The presence of terms like 'registration statement,' 'prospectus,' and 'offering' indicates this is a capital raising document. It is not an annual report, earnings release, or management discussion. The document is not a transcript, audit report, or governance information. It is clearly related to financing activities and fundraising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support a high confidence in this classification.
2017-02-02 English
FREE WRITING PROSPECTUS
Capital/Financing Update Classification · 95% confidence The document is titled 'FREE WRITING PROSPECTUS' and references a public offering filed pursuant to Rule 433 of the Securities Act of 1933. It includes detailed information about the offering, the issuer, use of proceeds, management team, development pipeline, and financial overview. The document is a marketing communication related to a securities offering, not a financial report or earnings release. It is not an annual or interim report, nor a regulatory filing in the sense of officer certifications or voting results. The document is a prospectus-type filing related to capital raising activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial (13,938 characters), indicating it is the actual prospectus communication, not just an announcement of a report.
2017-01-23 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.